Patent Oppositions in pain and inflammation drugs industry

Explore the competitive field of pain and inflammation drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in pain and inflammation drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the pain and inflammation drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the pain and inflammation drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Feb 12, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEJan 12, 2026BRAND MURRAY FULLER
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEDec 19, 2025HAMM & WITTKOPP
Compositions And Methods For Improving Mitochondrial Function And Treating Neurodegenerative Diseases And Cognitive DisordersAMAZENTISDec 11, 2025MICROBIOTA MED SP Z OO
Compositions And Methods For Improving Mitochondrial Function And Treating Neurodegenerative Diseases And Cognitive DisordersAMAZENTISDec 11, 2025MICROBIOTA MED SP Z OO
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEDec 8, 2025TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBB
Combination Of Collagen Peptide And Whey Protein For Use In A Condition Of The Skeletal TissueROUSSELOTNov 12, 2025COMPAGNIE GERVAIS DANONE
Combination Of Collagen Peptide And Whey Protein For Use In A Condition Of The Skeletal TissueROUSSELOTNov 7, 2025FRESENIUS KABI DEUTSCHLAND
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEOct 24, 2025CAMULON
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEOct 1, 2025ELKINGTON AND FIFE
Processes For Preparing Jak Inhibitors And Related Intermediate CompoundsINCYTEAug 12, 2025HAMM & WITTKOPP

To stay ahead in the competitive pain and inflammation drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the pain and inflammation drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Feb 12, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Aug 20, 2025Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPE5
May 29, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE5
Jul 27, 2022Use Of Dpp Iv InhibitorsBOEHRINGER INGELHEIM5
Dec 25, 2024Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALS4
Jul 22, 2020(1R, 2R)-3-(Dimenthyl Amino-1-Ethyl-2-Methyl-Propyl) Phenol For Treating Painful InflammationsGRNENTHAL4
May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneCELGENE3
Dec 20, 2023Pharmaceutical Compositions Comprising A Jak InhibitorGALAPAGOS3
Mar 27, 2019Corticosteroid CompositionsMERITAGE PHARMA2
Sep 14, 2022A Xanthine Derivative As Dpp-4 Inhibitor For Use In The Treatment Of Sirs And/Or SepsisBOEHRINGER INGELHEIM2